Antimicrobial resistance and therapy of staphylococcus aureus infections

Staphylococcus Aureus: Molecular and Clinical Aspects

Volumn , Issue , 2004, Pages 237-267

  Chambers, Henry F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947319465     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-898563-96-9.50011-7     Document Type: Chapter

References (143)

1. K.E. Aldridge., A. Janney., et al. Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations Antimicrob Agents Chemother 28 1985 634-638.
2. G.L. Archer., J.P. Coughter., et al. Plasmid-encoded trimethoprim resistance in staphylococci Antimicrob Agents Chemother 29 1986 733-740.
3. G.L. Archer., D.M. Niemeyer., et al. Dissemination among staphylococci of DNA sequences associated with methicillin resistance Antimicrob Agents Chemother 38 1994 447-454.
4. A.J. Berry., J.L. Johnston., et al. Imipenem therapy of experimental Staphylococcus epidermidis endocarditis Antimicrob Agents Chemother 29 1986 748-752.
5. S. Boyle-Vavra., S.K. Berke., et al. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates Antimicrob Agents Chemother 44 2000 272-277.
6. S. Boyle-Vavra., J. Hahm., et al. Structural and topological differences between a glycopeptide- intermediate clinical strain and glycopeptide-susceptible strains of Staphylococcus aureus revealed by atomic force microscopy Antimicrob Agents Chemother 44 2000 3456-3460.
7. A. Brisson-Noel., P. Delrieu., et al. Inactivation of lincosaminide antibiotics in Staphylococcus. Identification of lincosaminide O-nucleotidyltransferases and comparison of the corresponding resistance genes J Biol Chem 263 1988 15880-15887.
8. R.E. Bryant., R.H. Alford Unsuccessful treatment of staphylococcal endocarditis with cefazolin Jama 237 1977 569-570.
9. P. Calain., K.H. Krause., et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections J Infect Dis 155 1987 187-191.
10. L. Cantoni., A. Wenger., et al. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats J Infect Dis 159 1989 989-993.
11. T.C. Carpenter., C.J. Hackbarth., et al. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus Antimicrob Agents Chemother 30 1986 382-384.
12. J. Carrizosa., W.D. Kobasa., et al. Effectiveness of nafcillin, methicillin, and cephalothin in experimental Staphylococcus aureus endocarditis Antimicrob Agents Chemother 15 1979 735-737.
13. J. Carrizosa., W.D. Kobasa., et al. Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits Antimicrob Agents Chemother 18 1980 562-565.
14. J. Carrizosa., J. Santoro., et al. Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin Antimicrob Agents Chemother 13 1978 74-77.
15. CDC. (2002). Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 51 565-567.
16. H.F. Chambers Coagulase-negative staphylococci resistant to beta-lactam antibiotics in vivo produce penicillin-binding protein 2a Antimicrob Agents Chemother 31 1987 1919-1924.
17. H.F. Chambers Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus J Antimicrob Chemother 30 Suppl A 1992 117-122.
18. H.F. Chambers In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a Antimicrob Agents Chemother 39 1995 462-466.
19. H.F. Chambers., G. Archer., et al. Low-level methicillin resistance in strains of Staphylococcus aureus Antimicrob Agents Chemother 33 1989 424-428.
20. H.F. Chambers., M. Kartalija., et al. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits J Infect Dis 171 1995 897-902.
21. H.F. Chambers., R.T. Miller., et al. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy Ann Intern Med 109 1988 619-624.
22. H.F. Chambers., J. Mills., et al. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus Rev Infect Dis 6 Suppl 4 1984 S870-S874.
23. H.F. Chambers., Q. Xiang., et al. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus Antimicrob Agents Chemother 43 1999 2742-2746.
24. C.E. Cherubin., S.R. Nair Clindamycin in infective endocarditis JAMA 239 1978 626-627.
25. C. Chuard., M. Herrmann., et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations Antimicrob Agents Chemother 35 1991 2611-2616.
26. D. Clemett., A. Markham Linezolid Drugs 59 2000 815-827 discussion 828.
27. M.W. Climo., R.L. Patron., et al. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin Antimicrob Agents Chemother 43 1999 1747-1753.
28. I. Couto., H. de Lencastre., et al. Ubiquitous presence of a mecA homologue in natural isolates of Staphylococcus sciuri Microb Drug Resist 2 1996 377-391.
29. L. Cui., H. Murakami., et al. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50 Antimicrob Agents Chemother 44 2000 2276-2285.
30. C.F. Dailey., C.L. Dileto-Fang., et al. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 2001 2304-2308.
31. G.E. Dale., C. Broger., et al. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance J Mol Biol 266 1997 23-30.
32. G.E. Dale., C. Broger., et al. Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of Staphylococcus epidermidis ATCC 14990: the origin of the trimethoprim-resistant S1 DHFR from Staphylococcus aureus? J Bacteriol 177 1995 2965-2970.
33. T.E. Daum., D.R. Schaberg., et al. Increasing resistance of Staphylococcus aureus to ciprofloxacin Antimicrob Agents Chemother 34 1990 1862-1863.
34. M. de Gorgolas., P. Aviles., et al. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim- sulfamethoxazole and antibiotics that inhibit cell wall synthesis Antimicrob Agents Chemother 39 1995 953-957.
35. D.I. Diekema., R.N. Jones Oxazolidinones: a review Drugs 59 2000 7-16.
36. R.H. Drew., J.R. Perfect., et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group J Antimicrob Chemother 46 2000 775-784.
37. R. Dworkin., G. Modin., et al. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis Antimicrob Agents Chemother 34 1990 1014-1016.
38. R.J. Dworkin., B.L. Lee., et al. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin [see comments] Lancet 2 1989 1071-1073.
39. R.E. Eckart., D.R. Hospenthal., et al. Response of complicated methicillin-resistant Staphylococcus aureus endocarditis to the addition of trovafloxacin Pharmacotherapy 20 2000 589-592.
40. W.F. Ehni., L.B. Reller Short-course therapy for catheter-associated Staphylococcus aureus bacteremia Arch Intern Med 149 1989 533-536.
41. L.P. Elwell., H.R. Wilson., et al. In vitro and in vivo efficacy of the combination trimethoprim- sulfamethoxazole against clinical isolates of methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 29 1986 1092-1094.
42. M.C. Enright., D.A. Robinson., et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) Proc Natl Acad Sci U S A 99 2002 7687-7692.
43. J.M. Entenza., H. Drugeon., et al. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500 Antimicrob Agents Chemother 39 1995 1419-1424.
44. B. Fantin., R. Leclercq., et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus Antimicrob Agents Chemother 39 1995 400-405.
45. R.J. Faville Jr., D.E. Zaske., et al. Staphylococcus aureus endocarditis. Combined therapy with vancomycin and rifampin Jama 240 1978 1963-1965.
46. L. Ferrero., B. Cameron., et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones Mol Microbiol 13 1994 641-653.
47. J. Fortun., J.A. Perez-Molina., et al. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers Antimicrob Agents Chemother 39 1995 525-528.
48. V.G. Fowler Jr., L.L. Sanders., et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients Clin Infect Dis 27 1998 478-486.
49. M. Franciolli., J. Bille., et al. Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus J Infect Dis 163 1991 514-523.
50. J.L. Gerberding., C. Miick., et al. Comparison of conventional susceptibility tests with direct detection of penicillin-binding protein 2a in borderline oxacillin-resistant strains of Staphylococcus aureus Antimicrob Agents Chemother 35 1991 2574-2579.
51. D.N. Gilbert., C.A. Wood., et al. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon Antimicrob Agents Chemother 35 1991 79-87.
52. Y. Glupczynski., H. Lagast., et al. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria Antimicrob Agents Chemother 29 1986 52-57.
53. M.B. Goetz., J. Sayers Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination J Antimicrob Chemother 32 1993 325-334.
54. P.L. Goldman., R.G. Petersdorf Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus J Infect Dis 141 1980 331-337.
55. G.D. Gordon., P.J. Commerford The treatment of infective endocarditis [editorial] S Afr Med J. 73 1988 690.
56. R.N. Greenberg., D.J. Kennedy., et al. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin Antimicrob Agents Chemother 31 1987 151-155.
57. D.R. Guay., K. Vance-Bryan., et al. Comparison of vancomycin pharmacokinetics in hospitalized elderly and young patients using a Bayesian forecaster J Clin Pharmacol 33 1993 918-922.
58. I.C. Hampele., A. D’Arcy., et al. Structure and function of the dihydropteroate synthase from Staphylococcus aureus J Mol Biol 268 1997 21-30.
59. T. Hau Efficacy and safety of linezolid in the treatment of skin and soft tissue infections Eur J Clin Microbiol Infect Dis 21 2002 491-498.
60. A.W. Heldman., T.V. Hartert., et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy Am J Med 101 1996 68-76.
61. K. Hiramatsu Molecular evolution of MRSA Microbiol Immunol 39 1995 531-543.
62. K. Hiramatsu The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan Am J Med 104 1998 7S-10S.
63. K. Hiramatsu., N. Aritaka., et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin [see comments] Lancet 350 1997 1670-1673.
64. K. Hiramatsu., H. Hanaki., et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility [letter] [see comments] J Antimicrob Chemother 40 1997 135-136.
65. L. Hirano., A.S. Bayer Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci Antimicrob Agents Chemother 35 1991 685-690.
66. D.C. Hooper Emerging mechanisms of fluoroquinolone resistance Emerg Infect Dis 7 2001 337-341.
67. T. Ito., Y. Katayama., et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 2001 1323-1336.
68. T. Ito., Y. Katayama., et al. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315 Antimicrob Agents Chemother 43 1999 1449-1458.
69. J.A. Jernigan., B.M. Farr Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis Ann Intern Med 119 1993 304-311.
70. G.W. Kaatz., S.M. Seo., et al. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis Antimicrob Agents Chemother 33 1989 1184-1187.
71. G.W. Kaatz., S.M. Seo., et al. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis J Infect Dis 162 1990 103-108.
72. A.W. Karchmer., G.L. Archer., et al. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy Ann Intern Med 98 1983 447-455.
73. Y. Katayama., T. Ito., et al. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus Antimicrob Agents Chemother 44 2000 1549-1555.
74. D.S. Kernodle., D.C. Classen., et al. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections Jama 263 1990 961-966.
75. O. Korzeniowski., M.A. Sande Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study Ann Intern Med 97 1982 496-503.
76. B. Kreiswirth., J. Kornblum., et al. Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus Science 259 1993 227-230.
77. M.T. Lawlor., M.C. Sullivan., et al. Treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus with minocycline J Infect Dis 161 1990 812-814.
78. D.P. Levine., B.S. Fromm., et al. Slow response to vancomycin or vancomycin plus rifampin in methicillin- resistant Staphylococcus aureus endocarditis Ann Intern Med 115 1991 674-680.
79. G. Lina., A. Quaglia., et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci Antimicrob Agents Chemother 43 1999 1062-1066.
80. G.J. Malanoski., M.H. Samore., et al. Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters Arch Intern Med 155 1995 1161-1166.
81. N. Markowitz., E.L. Quinn., et al. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection Ann Intern Med 117 1992 390-398.
82. R.M. Massanari., S.T. Donta The efficacy of rifampin as adjunctive therapy in selected cases of staphylococcal endocarditis Chest 73 1978 371-375.
83. L.K. McDougal., C. Thornsberry The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins J Clin Microbiol 23 1986 832-839.
84. K.B. Menda., S.L. Gorbach Favorable experience with bacterial endocarditis in heroin addicts Ann Intern Med 78 1973 25-32.
85. M.H. Miller., M.A. Wexler., et al. Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants Antimicrob Agents Chemother 14 1978 336-343.
86. R.C. Moellering Jr., D.J. Krogstad., et al. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function Rev Infect Dis 1981 S230-S235 3 suppl.
87. B. Moreira., S. Boyle-Vavra., et al. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus Antimicrob Agents Chemother 41 1997 1788-1793.
88. L. Mulazimoglu., S.D. Drenning., et al. Vancomycin-gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 40 1996 1534-1535.
89. M.E. Mulligan., P.J. Ruane., et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization Am J Med 82 1987 215-219.
90. P. Nicholas., B.R. Meyers., et al. Concentrations of clindamycin in human bone Antimicrob Agents Chemother 8 1975 20-21.
91. D.P. Nicolau., C.D. Freeman., et al. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 38 1994 1515-1518.
92. C.W. Norden Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents Rev Infect Dis 5 Suppl 3 1983 S491-S494.
93. M.P. Oramas-Shirey., L.V. Buchanan., et al. Efficacy of linezolid in a staphylococcal endocarditis rabbit model J Antimicrob Chemother 47 2001 349-352.
94. R.H. Parker., B.E. Fossieck Jr. Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis Ann Intern Med 93 1980 832-834.
95. J. Pavie., A. Lefort., et al. Efficacies of Quinupristin-Dalfopristin Combined with Vancomycin In Vitro and in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus in Relation to Cross-Resistance to Macrolides, Lincosamides, and Streptogramin B- Type Antibiotics Antimicrob Agents Chemother 46 2002 3061-3064.
96. A. Pefanis., C. Thauvin-Eliopoulos., et al. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus Antimicrob Agents Chemother 37 1993 507-511.
97. L.R. Peterson., J.N. Quick., et al. Emergence of ciprofloxacin resistance in nosocomial methicillin- resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization Arch Intern Med 150 1990 2151-2155.
98. M.T. Reymann., H.P. Holley Jr., et al. Persistent bacteremia in staphylococcal endocarditis Am J Med 65 1978 729-737.
99. E. Ribera., J. Gomez-Jimenez., et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis. A randomized, controlled trial Ann Intern Med 125 1996 969-974.
100. J.P. Rissing Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones Clin Infect Dis 25 1997 1327-1333.
101. W. Rodriguez., S. Ross., et al. Clindamycin in the treatment of osteomyelitis in children: a report of 29 cases Am J Dis Child 131 1977 1088-1093.
102. E. Rubinstein., S. Cammarata., et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double- blind, multicenter study Clin Infect Dis 32 2001 402-412.
103. M.J. Rybak., L.M. Albrecht., et al. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers Antimicrob Agents Chemother 34 1990 792-795.
104. A. Sander., M. Beiderlinden., et al. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci Intensive Care Med 28 2002 1157-1160.
105. H.J. Schaad., C. Chuard., et al. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 38 1994 1703-1710.
106. F.J. Schmitz., A.C. Fluit., et al. The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals J Antimicrob Chemother 43 1999 253-259.
107. R.S. Schwalbe., J.T. Stapleton., et al. Emergence of vancomycin resistance in coagulase-negative staphylococci N Engl J Med 316 1987 927-931.
108. P.G. Scotton., R. Rigoli., et al. Combination of quinupristin/dalfopristin and glycopeptide in severe methicillin-resistant staphylococcal infections failing previous glycopeptide regimens Infection 30 2002 161-163.
109. D.M. Shlaes., L.B. Rice Bacterial resistance to the cyclic glycopeptides Trends Microbiol 2 1994 385-388.
110. D.M. Shlaes., J.H. Shlaes Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin Clin Infect Dis 20 1995 1071-1073.
111. K. Sieradzki., A. Tomasz A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus FEMS Microbiol Lett 142 1996 161-166.
112. K. Sieradzki., A. Tomasz Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus J Bacteriol 179 1997 2557-2566.
113. K. Sieradzki., P. Villari., et al. Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci Antimicrob Agents Chemother 42 1998 100-107.
114. P.M. Small., H.F. Chambers Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users Antimicrob Agents Chemother 34 1990 1227-1231.
115. S.M. Smith., R.H. Eng., et al. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations Antimicrob Agents Chemother 33 1989 181-184.
116. S. Sreedharan., M. Oram., et al. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli J Bacteriol 172 1990 7260-7262.
117. J.M. Steckelberg., M.S. Rouse., et al. Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis Antimicrob Agents Chemother 37 1993 554-558.
118. D.L. Stevens., D. Herr., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 34 2002 1481-1490.
119. M. Tanaka., T. Wang., et al. Mechanism of quinolone resistance in Staphylococcus aureus J Infect Chemother 6 2000 131-139.
120. D.E. Taylor., A. Chau Tetracycline resistance mediated by ribosomal protection Antimicrob Agents Chemother 40 1996 1-5.
121. P. Tebas., R. Martinez Ruiz., et al. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis J Infect Dis 163 1991 204-205.
122. F.C. Tenover., M.V. Lancaster., et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides [published erratum appears in J Clin Microbiol 1998 Jul;36(7):2167] J Clin Microbiol 36 1998 1020-1027.
123. R.L. Then., I. Kohl., et al. Frequency and transferability of trimethoprim and sulfonamide resistance in methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis J Chemother 4 1992 67-71.
124. C. Thornsberry Susceptibility of clinical bacterial isolates to ciprofloxacin in the United States Infection 22 1994 S80-S89.
125. C. Thornsberry., B.C. Hill., et al. Rifampin: spectrum of antibacterial activity Rev Infect Dis 5 Suppl 3 1983 S412-S417.
126. A. Tomasz., H.B. Drugeon., et al. New mechanism for methicillin resistance in Staphylococcus aureus: clinical isolates that lack the PBP 2a gene and contain normal penicillin-binding proteins with modified penicillin-binding capacity Antimicrob Agents Chemother 33 1989 1869-1874.
127. M. Torres-Tortosa., M. de Cueto., et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis. Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cadiz Eur J Clin Microbiol Infect Dis 13 1994 559-564.
128. K. Trzcinski., B.S. Cooper., et al. Expression of resistance to tetracyclines in strains of methicillin- resistant Staphylococcus aureus J Antimicrob Chemother 45 2000 763-770.
129. S. Tsiodras., H.S. Gold., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus Lancet 358 2001 207-208.
130. K. Ubukata., R. Nonoguchi., et al. Homology of mecA gene in methicillin-resistant Staphylococcus haemolyticus and Staphylococcus simulans to that of Staphylococcus aureus Antimicrob Agents Chemother 34 1990 170-172.
131. F.A. Waldvogel Use of quinolones for the treatment of osteomyelitis and septic arthritis Rev Infect Dis 11 Suppl 5 1989 S1259-S1263.
132. C.T. Walsh Vancomycin resistance: decoding the molecular logic Science 261 1993 308-309.
133. C.T. Walsh., S.L. Fisher., et al. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story Chem Biol 3 1996 21-28.
134. C. Watanakunakorn Clindamycin therapy of Staphylococcus aureus endocarditis: clinical relapse and development of resistance to clindamycin, lincomycin, and erythromycin Amer J Med 60 1976 419-425.
135. C. Whitener., G.M. Caputo., et al. Endocarditis due to coagulase-negative staphylococci. Microbiologic, epidemiologic, and clinical considerations Infect Dis Clin North Am 7 1993 81-96.
136. W.R. Wilson., A.W. Karchmer., et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association Jama 274 1995 1706-1713.
137. W.R. Wilson., A.W. Karchmer., et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association [see comments] Jama 274 1995 1706-1713.
138. S. Wu., C. Piscitelli., et al. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri [published errata appear in Microb Drug Resist 1997 Summer;3(2):212 and 1997 Fall;3(3):288] Microb Drug Resist 2 1996 435-441.
139. J.H. Yuk., M.C. Dignani., et al. Minocycline as an alternative antistaphylococcal agent Rev Infect Dis 13 1991 1023-1024.
140. V. Zarrouk., B. Bozdogan., et al. Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics Antimicrob Agents Chemother 45 2001 1244-1248.
141. W. Zimmerli., A.F. Widmer., et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group Jama 279 1998 1537-1541.
142. G.E. Zurenko., B.H. Yagi., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Antimicrob Agents Chemother 40 1996 839-845.
143. D.J. Zygmunt., C.W. Stratton., et al. Characterization of four beta-lactamases produced by Staphylococcus aureus Antimicrob Agents Chemother 36 1992 440-445.